Daily Stock Opinions and Ratings

Opinions

Jim Cramer - Mad Money CRISPR Therapeutics AG CRSP-Q BUY Aug 07, 2024

They have some explosive technology. He believes in it.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$47.430

Stock price when the opinion was issued

biotechnology

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

They produce a gene-editing tool that splices DNA that has the potential of curing diseases such as Huntington's Chorea and cancer. It's new technology, but he can't think of another company doing this. This segment is very rich and a trading opportunity at best.

COMMENT

A small company that develops transformative gene medications. They are a small fish in a big sea. A recent transaction with a pharma company allows them to scale out their product, but it is still early. (Analysts’ price target is $58.05)

RISKY

A great spec. It's a genetic engineering company so it's bought on spec, not earnings.

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Premium members

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

Biopharmaceutical company building gene editing based medicines for serious diseases. Riskier play, but gene editing would be a massive breakthrough and they have been the leaders in that space for a while. New to the trending stocks with 13 mentions in the past 24 hours.

DON'T BUY

Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.

HOLD

Recent improvements in R&D have been major gain in the business. Is hard to predict future of business given nature of health discoveries. Would recommend holding it.

COMMENT

Is trading at a fraction of a few years ago. If you know about gene technology, maybe buy this, but doesn't know a lot about this science or business.

PARTIAL BUY

He sees this company mentioned in many science papers, but the stock has been a tough own. Overall, he likes it. Buy some now and more if it goes lower. How can this company keep losing money?

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money CRISPR Therapeutics AG CRSP-Q BUY Aug 07, 2024

You might be interested:

CRISPR Therapeutics AG(CRSP-Q)

CRISPR Therapeutics AG(CRSP-Q)

CRISPR Therapeutics AG(CRSP-Q)

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Premium members

CRISPR Therapeutics AG(CRSP-Q)

CRISPR Therapeutics AG(CRSP-Q)

CRISPR Therapeutics AG(CRSP-Q)

CRISPR Therapeutics AG(CRSP-Q)

CRISPR Therapeutics AG(CRSP-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights